Mark Cuban: Lower net pricing from big pharma could cut U.S. medication costs by 40 percent

Mark Cuban: Lower net pricing from big pharma could cut U.S. medication costs by 40 percent
Cuban urges pharma pricing change

Mark Cuban stated on social media that if major pharmaceutical firms sold medications to the three largest U.S. distributors at net prices, rather than list prices, average patients could save about 40 percent on specialty and brand-name prescriptions. Cuban called attention to the current pricing system, suggesting a straightforward switch could result in substantial savings for consumers. He also urged several U.S. lawmakers to consider this change while referencing notable figures in the ongoing public debate over drug costs.

Cuban wrote: ''If big pharma sold to big 3 distributors at net prices rather than list prices, patients would save on average 40pct on their specialty and brand medications.''

Cuban’s latest remarks on pharmaceutical pricing reform align with his ongoing advocacy for the cost plus model in health insurance, a strategy he has argued presents significant savings for both patients and self-insured employers. His emphasis on human judgment in assessing systemic outcomes, particularly in areas where technology and policy intersect, further underscores recent industry debates around healthcare accessibility and innovation. For further context, see his perspective on the advantages of Cost Plus Drugs for self-insured employers and his argument that humans retain an edge over AI in understanding the real-world impact of healthcare decisions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.